|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Breakpoint characterization of the ret/PTC oncogene in human papillary thyroid carcinoma.
|
8634704 |
1995 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
RET/PTC oncogene activation is an early event in thyroid carcinogenesis.
|
7566982 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The human PTC gene appears to be crucial for proper embryonic development and for tumor suppression.
|
8658145 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We analyzed 60 thyroid carcinomas for ret/PTC expression to determine correlation with clinical history, disease stage, or tumor morphology.
|
8784097 |
1996 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The ret/PTC oncogene is unique to papillary thyroid cancer.
|
8784097 |
1996 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Its 5' end was found fused to the catalytic domain of the RET protooncogene to generate RET/PTC 1, the most common form of PTC oncogenes in human papillary thyroid carcinoma.
|
9067436 |
1996 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
PTC-1113A is, to our knowledge, the single papillary thyroid cancer cell line demonstrating evidence of gene amplification.
|
8780751 |
1996 |
|
Papillary thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Proto-RET is rearranged in the new human papillary thyroid cancer cell line PTC-1113A.
|
8689603 |
1996 |
|
Thyroid carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We analyzed 60 thyroid carcinomas for ret/PTC expression to determine correlation with clinical history, disease stage, or tumor morphology.
|
8784097 |
1996 |
|
Carcinoma, Basal Cell
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Heritable mutations in BCNS patients and a somatic mutation in a sporadic BCC were identified in a human homolog of the Drosophila patched (ptc) gene.
|
8658145 |
1996 |
|
Carcinoma, Papillary
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Expression of the RET/PTC fusion gene as a marker for papillary carcinoma in Hashimoto's thyroiditis.
|
9001272 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The percentage of proliferating cells was significantly different among the histotypes, increasing with tumour aggressiveness (from the mean value of 3.1 for PTC to 5.6 for PDC and 51.8 for UC).
|
9052406 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that inactivation of some tumor suppressor gene(s) on 9q other than PTC contributes to the development of squamous cell carcinomas in these tissues.
|
9140104 |
1997 |
|
Papillary thyroid carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
All thyroid specimens, in addition to histological and immunohistological examinations, were also specifically studied for activation of the RET-PTC oncogene, that seems to be restricted to papillary thyroid carcinoma.
|
9354893 |
1997 |
|
Carcinogenesis
|
0.100 |
GeneticVariation
|
phenotype |
BEFREE |
To investigate the possible role of the PTC gene on chromosome 9q22.3, that was identified as the cause of nevoid basal cell carcinoma syndrome, during carcinogenesis in esophagus and lung, we examined 20 esophageal squamous cell carcinomas and 10 squamous cell carcinomas of the lung for mutations in any coding exon of PTC.
|
9140104 |
1997 |
|
Squamous cell carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Our results suggest that inactivation of some tumor suppressor gene(s) on 9q other than PTC contributes to the development of squamous cell carcinomas in these tissues.
|
9140104 |
1997 |
|
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Frequent allelic losses on chromosome 9 are seen in a wide variety of human tumors; moreover, two genes (P16 and PTC) whose mutant alleles confer predispositions to some inherited cancer syndromes have been identified on this chromosome.
|
9818027 |
1998 |
|
Malignant neoplasm of thyroid
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data suggest that: (1) the incidence of FAP-associated thyroid cancer probably has been underestimated in the past; (2) intensive screening could detect a larger than expected number of thyroid carcinomas; (3) systematic screening is recommended in patients with ocular patches and genetic mutation in exon 15; (4) Hashimoto-like findings do not exclude carcinoma but are a frequent accompanying finding; (5) despite frequent multicentricity and early lymph node involvement, FAP-associated thyroid tumors seem to have an excellent prognosis, in particular those showing ret-PTC activation.
|
9841749 |
1998 |
|
Carcinoma, Papillary
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present data do not support a major geographic difference in the prevalence of ret/PTC rearrangements in papillary carcinomas between Japan, the United States, and Italy.
|
9669285 |
1998 |
|
Carcinoma, Papillary
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study demonstrates that all thyroid carcinomas harboring activating RET rearrangements exhibit a well-differentiated phenotype, that of papillary carcinoma, and indicates that the subset of RET/PTC-positive papillary carcinomas do not progress to more aggressive, less differentiated tumor phenotypes.
|
9516913 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We tested a resulting prediction that RET/PTC expression in thyroid epithelium should be sufficient to cause the changes in nuclear morphology diagnostic of this tumor.
|
9811335 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The prevalence of ret/PTC in these tumors varies widely, from 0% to 87%, among patient series from different geographical regions.
|
9669285 |
1998 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Present data suggest that: (1) the incidence of FAP-associated thyroid cancer probably has been underestimated in the past; (2) intensive screening could detect a larger than expected number of thyroid carcinomas; (3) systematic screening is recommended in patients with ocular patches and genetic mutation in exon 15; (4) Hashimoto-like findings do not exclude carcinoma but are a frequent accompanying finding; (5) despite frequent multicentricity and early lymph node involvement, FAP-associated thyroid tumors seem to have an excellent prognosis, in particular those showing ret-PTC activation.
|
9841749 |
1998 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
|
9861322 |
1998 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Distinct multiple RET/PTC gene rearrangements in multifocal papillary thyroid neoplasia.
|
9814501 |
1998 |